Zentalis Pharmaceuticals
ZNTL
ZNTL
142 hedge funds and large institutions have $1.34B invested in Zentalis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
13% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 38
9% more capital invested
Capital invested by funds: $1.24B → $1.34B (+$107M)
4.78% more ownership
Funds ownership: 115.41% → 120.2% (+4.8%)
Holders
142
Holding in Top 10
4
Calls
$1.14M
Puts
$36K
Top Buyers
| 1 | +$23.9M | |
| 2 | +$15.4M | |
| 3 | +$12.8M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.23M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$8.59M |
Top Sellers
| 1 | -$15M | |
| 2 | -$9.95M | |
| 3 | -$3.82M | |
| 4 |
IHAM
Integral Health Asset Management
New York
|
-$3.79M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$2.95M |